Philip Seo, MD
Rheumatology · Baltimore, MDNPI 1225084130
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $63,373 of the $83,629 with a category attached, or 75.8%. 7 manufacturers reported payments, led by Amgen at 24.1% of the total. Reporting peaked in 2019 at $34,016 and has fallen 85.6% since, to $4,903 in 2024. Among rheumatology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $1639.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- Sanofi$18K
- GSK$16K
- F. Hoffmann-la Roche AG$16K
- Janssen Research & Development, LLC$11K
- Bristol Myers Squibb$3K
- plus $100 from 1 others
What the payments were for
- Consulting fees$63,37376%
- Travel & lodging$19,67124%
- Food & beverage$5851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $20,125 |
| Sanofi | 8 | $17,841 |
| GSK | 22 | $16,083 |
| F. Hoffmann-la Roche AG | 5 | $15,580 |
| Janssen Research & Development, LLC | 5 | $10,500 |
| Bristol Myers Squibb | 2 | $3,400 |
| Cardinal Health 110 LLC | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$83,629 in reported general payments places this provider in the 90th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azathioprine | 20 | $1,747 |
| MethotrexateMethotrexate Sodium | 24 | $928 |
| Prednisone | 47 | $655 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $80 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Baltimore
- Michelle PetriBaltimore$381K
- Marc HochbergBaltimore$124K
- Clifton BinghamBaltimore$117K
- Lisa ChristopherBaltimore$92K
- Laura HummersBaltimore$80K
- Rachel WallworkBaltimore$71K
- Thomas Grader BeckBaltimore$55K
- Andrea FavaBaltimore$38K
- Christopher MecoliBaltimore$34K
- Laura CappelliBaltimore$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.